Publication | Closed Access

A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer

MedicineCombined TrabectedinGynecologyRecurrent Ovarian CancerTumor TargetingCancer TreatmentOncologyRadiation OncologyGynecology OncologyPhase 3Ovarian Cancer